Indivior Pharmaceuticals (INDV) Cash from Financing Activities (2024 - 2026)

Indivior Pharmaceuticals' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 141.18% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at -$6.0 million (up 90.48% YoY), while the FY2025 annual figure was -$30.0 million, up 70.59% from the prior year.
• Cash from Financing Activities was $7.0 million for Q1 2026 at Indivior Pharmaceuticals, up from -$5.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $40.0 million in Q4 2024 to a low of -$56.0 million in Q1 2024.
• Historically, Cash from Financing Activities has averaged -$13.9 million across 3 years, with a median of -$5.0 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities plunged 112.5% in 2025, then jumped 141.18% in 2026.
• A 3-year view of Cash from Financing Activities shows it stood at $40.0 million in 2024, then slumped by 112.5% to -$5.0 million in 2025, then surged by 240.0% to $7.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $7.0 million (Q1 2026), -$5.0 million (Q4 2025), and -$3.0 million (Q3 2025), per Business Quant data.